U.S. markets closed
  • S&P Futures

    4,164.50
    +6.75 (+0.16%)
     
  • Dow Futures

    34,333.00
    +77.00 (+0.22%)
     
  • Nasdaq Futures

    13,326.75
    +23.25 (+0.17%)
     
  • Russell 2000 Futures

    2,229.90
    +4.40 (+0.20%)
     
  • Crude Oil

    66.33
    +0.06 (+0.09%)
     
  • Gold

    1,868.70
    +1.10 (+0.06%)
     
  • Silver

    28.37
    +0.10 (+0.34%)
     
  • EUR/USD

    1.2158
    +0.0001 (+0.01%)
     
  • 10-Yr Bond

    1.6400
    +0.0050 (+0.31%)
     
  • Vix

    19.72
    +0.91 (+4.84%)
     
  • GBP/USD

    1.4148
    +0.0011 (+0.08%)
     
  • USD/JPY

    109.2710
    +0.0710 (+0.07%)
     
  • BTC-USD

    43,488.06
    -2,927.84 (-6.31%)
     
  • CMC Crypto 200

    1,200.49
    +2.57 (+0.21%)
     
  • FTSE 100

    7,032.85
    -10.76 (-0.15%)
     
  • Nikkei 225

    27,824.83
    -259.67 (-0.92%)
     

Karuna Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Karuna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that Steve Paul, M.D., chief executive officer, president and chairman, will present at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021 at 10:50 a.m. EST.

A live webcast of the presentation will be available on the Investor Relations page of Karuna’s website at investors.karunatx.com. A replay of the webcast will also be archived for up to 30 days on Karuna’s website following the conference.

About Karuna Therapeutics

Karuna Therapeutics is a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions. At Karuna, we understand there is a need for differentiated and more effective treatments that can help patients navigate the challenges presented by these severe and disabling disorders. Utilizing our extensive knowledge of neuroscience, we are harnessing the untapped potential of the brain in pursuit of novel pathways to develop medicines that make meaningful differences in peoples’ lives. For more information, please visit www.karunatx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210105005315/en/

Contacts

Investor:
Alexis Smith
518-338-8990
asmith@karunatx.com